Multiple-purpose immunotherapy for cancer
- PMID: 26653546
- DOI: 10.1016/j.biopha.2015.10.020
Multiple-purpose immunotherapy for cancer
Abstract
Anti-cancer vaccination is a useful strategy to elicit antitumor immune responses, while overcoming immunosuppressive mechanisms. Whole tumor cells or lysates derived thereof hold more promise as cancer vaccines than individual tumor-associated antigens (TAAs), because vaccinal cells can elicit immune responses to multiple TAAs. Cancer cell-based vaccines can be autologous, allogeneic or xenogeneic. Clinical use of xenogeneic vaccines is advantageous in that they can be most effective in breaking the preexisting immune tolerance to TAAs. An attractive protocol would be to combine vaccinations with immunostimulating and/or immunosuppression-blocking modalities. It is reasonable to anticipate that combined immunotherapeutic strategies will allow for substantial improvements in clinical outcomes in the near future.
Keywords: Antitumor immunoprotection; Cancer cell-based vaccines; Combined immunotherapy; Immunosuppression.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814. Hum Vaccin Immunother. 2015. PMID: 25933181 Free PMC article. Review.
-
Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?Vaccine. 2014 Jul 7;32(32):4015-24. doi: 10.1016/j.vaccine.2014.05.006. Epub 2014 May 14. Vaccine. 2014. PMID: 24837511 Review.
-
Cancer vaccines. Any future?Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):249-59. doi: 10.1007/s00005-011-0129-y. Epub 2011 Jun 5. Arch Immunol Ther Exp (Warsz). 2011. PMID: 21644030 Review.
-
Current developments with peptide-based human tumor vaccines.Curr Opin Oncol. 2009 Nov;21(6):524-30. doi: 10.1097/CCO.0b013e328331a78e. Curr Opin Oncol. 2009. PMID: 19770763 Review.
-
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.Immunol Rev. 2008 Apr;222:316-27. doi: 10.1111/j.1600-065X.2008.00605.x. Immunol Rev. 2008. PMID: 18364011 Review.
Cited by
-
Monoclonal antibodies in cancer immunotherapy.Mol Biol Rep. 2018 Dec;45(6):2935-2940. doi: 10.1007/s11033-018-4427-x. Epub 2018 Oct 11. Mol Biol Rep. 2018. PMID: 30311129 Review.
-
The new progress in cancer immunotherapy.Clin Exp Med. 2023 Jul;23(3):553-567. doi: 10.1007/s10238-022-00887-0. Epub 2022 Sep 15. Clin Exp Med. 2023. PMID: 36109471 Free PMC article. Review.
-
STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.J Exp Clin Cancer Res. 2017 Nov 7;36(1):156. doi: 10.1186/s13046-017-0623-0. J Exp Clin Cancer Res. 2017. PMID: 29115974 Free PMC article.
-
Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies.Biomed Res Int. 2020 Sep 17;2020:4956946. doi: 10.1155/2020/4956946. eCollection 2020. Biomed Res Int. 2020. PMID: 33015169 Free PMC article. Review.
-
Inflammation Control and Immunotherapeutic Strategies in Comprehensive Cancer Treatment.Metabolites. 2023 Jan 13;13(1):123. doi: 10.3390/metabo13010123. Metabolites. 2023. PMID: 36677048 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources